


JBJ-09-063 hydrochloride

Cat. No.:	HY-147183B
Molecular Formula:	C ₃₁ H ₃₀ ClFN ₄ O ₃ S
Molecular Weight:	593.11
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (168.60 mM; Need ultrasonic)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.6860 mL	8.4301 mL	16.8603 mL
	5 mM	0.3372 mL	1.6860 mL	3.3721 mL
	10 mM	0.1686 mL	0.8430 mL	1.6860 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

JBJ-09-063 hydrochloride is a mutant-selective allosteric EGFR inhibitor with IC₅₀s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFR L747S. JBJ-09-063 hydrochloride effectively reduces EGFR, Akt and ERK1/2 phosphorylation. JBJ-09-063 hydrochloride is effective across EGFR tyrosine kinase inhibitor (TKI)-sensitive and resistant models. JBJ-09-063 hydrochloride can be used for researching EGFR-mutant lung cancer^[1].

IC₅₀ & Target

EGFR L858R 0.147 nM (IC ₅₀)	EGFR L858R/T790M 0.063 nM (IC ₅₀)	EGFR L858R/T790M/C797S 0.083 nM (IC ₅₀)	EGFR L747S 0.396 nM (IC ₅₀)
--	--	--	--

In Vitro

JBJ-09-063 is remarkably effective at inhibiting cell growth and leads to a significant increase in apoptosis, even though H3255GR cells are resistant to gefitinib as a single agent, as they contain an EGFR T790M mutation^[1].
JBJ-09-063 is effective in H1975 cells exogenously expressing the osimertinib-resistant mutations^[1].
JBJ-09-063 exhibits IC₅₀s of 50 nM and 6 nM in Ba/F3 cell when use alone or combination with [Cetuximab](#) (HY-P9905)^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

JBJ-09-063 (3 mg/kg i.v., 20 mg/kg p.o.) exhibits favorable pharmacokinetics properties and is sufficiently stable to deliver good efficacy upon oral dosing^[2].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice ^[2]				
Dosage:	3 mg/kg for i.v., 20 mg/kg for p.o.				
Administration:	i.v. and p.o.; single dosage				
Result:	Pharmacokinetic Parameters of JBJ-09-063 in mice ^[2] .				
	Cl (mL/min/kg), i.v.	T _{1/2} (h)	V _{SS} (L/kg)	F (%)	AUC 8h (ng·h/mL)
	15.7	2.3	2.5	15	2398

REFERENCES

[1]. To C, et al. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. *Nat Cancer*. 2022 Apr;3(4):402-417.

[2]. Gero TW, Scott DA, et al. Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. *Bioorg Med Chem Lett*. 2022 Jul 15;68:128718.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA